Background And Purpose: Clinical decision support systems are a growing class of tools with the potential to impact healthcare. This study investigates the construction of a decision support system through which clinicians can efficiently identify which previously approved historical treatment plans are achievable for a new patient to aid in selection of therapy.
Material And Methods: Treatment data were collected for early-stage lung and postoperative oropharyngeal cancers treated using photon (lung and head and neck) and proton (head and neck) radiotherapy. Machine-learning classifiers were constructed using patient-specific feature-sets and a library of historical plans. Model accuracy was analyzed using learning curves, and historical treatment plan matching was investigated.
Results: Learning curves demonstrate that for these datasets, approximately 45, 60, and 30 patients are needed for a sufficiently accurate classification model for radiotherapy for early-stage lung, postoperative oropharyngeal photon, and postoperative oropharyngeal proton, respectively. The resulting classification model provides a database of previously approved treatment plans that are achievable for a new patient. An exemplary case, highlighting tradeoffs between the heart and chest wall dose while holding target dose constant in two historical plans is provided.
Conclusions: We report on the first artificial-intelligence based clinical decision support system that connects patients to past discrete treatment plans in radiation oncology and demonstrate for the first time how this tool can enable clinicians to use past decisions to help inform current assessments. Clinicians can be informed of dose tradeoffs between critical structures early in the treatment process, enabling more time spent on finding the optimal course of treatment for individual patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.radonc.2017.10.014 | DOI Listing |
Support Care Cancer
January 2025
Oral Diagnosis Department, Faculdade de Odontolodia de Piracicaba, Universidade de Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
Purpose: Oral mucositis (OM) reflects a complex interplay of several risk factors. Machine learning (ML) is a promising frontier in science, capable of processing dense information. This study aims to assess the performance of ML in predicting OM risk in patients undergoing head and neck radiotherapy.
View Article and Find Full Text PDFClin Rheumatol
January 2025
Department of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
Introduction/objectives: The study aimed to determine whether in children with newly diagnosed juvenile idiopathic arthritis (JIA) hepatitis B surface antibody (anti-HBs) differs from healthy children and to see whether the revaccination is safe and effective under JIA treatment.
Methods: Patients who were followed up with a diagnosis of JIA between January 2020 and February 2024 were included. The control group consisted of healthy children matched for age and gender.
Environ Monit Assess
January 2025
Department of Environmental Management, Graduate School of Agriculture, Kindai University, Nara, Japan.
Efficient agricultural management often relies on farmers' experiential knowledge and demands considerable labor, particularly in regions with challenging terrains. To reduce these burdens, the adoption of smart technologies has garnered increasing attention. This study proposes a convolutional neural network (CNN)-based model as a decision-support tool for smart irrigation in orchard systems, focusing on persimmon cultivation in mountainous regions.
View Article and Find Full Text PDFRadiology
January 2025
From the Departments of Radiology and Population Health, New York University Langone Medical Center, New York, NY (S.K.K.); Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Wash (R.G.); Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY (N.M., C.H.); Herbert Irving Comprehensive Cancer Center, New York, NY (C.H., E.B.E.); and Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY (E.B.E.).
Multi-cancer early detection (MCED) tests are already being marketed as noninvasive, convenient opportunities to test for multiple cancer types with a single blood sample. The technology varies-involving detection of circulating tumor DNA, fragments of DNA, RNA, or proteins unique to each targeted cancer. The priorities and tradeoffs of reaching diagnostic resolution in the setting of possible false positives and negatives remain under active study.
View Article and Find Full Text PDFClin Pharmacol Ther
January 2025
Center for Observational Research, Amgen Inc., Thousand Oaks, California, USA.
A compilation of factors over the past decade-including the availability of increasingly large and rich healthcare datasets, advanced technologies to extract unstructured information from health records and digital sources, advancement of principled study design and analytic methods to emulate clinical trials, and frameworks to support transparent study conduct-has ushered in a new era of real-world evidence (RWE). This review article describes the evolution of the RWE era, including pharmacoepidemiologic methods designed to support causal inferences regarding treatment effects, the role of regulators and other health authorities in establishing distributed real-world data networks enabling analytics at scale, and the many global guidance documents on principled methods of producing RWE. This article also highlights the growing opportunity for RWE to support decision making by regulators, health technology assessment groups, clinicians, patients, and other stakeholders and provides examples of influential RWE studies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!